ClinicalTrials.Gov registration of LUPUZOR™ Pivotal Phase III Trial

27th July 2015 - 11:35 am

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company is delighted to announce that registration with the U.S. National Institutes of Health – website has now gone ‘live’ confirming Lupuzor’s™ pivotal Phase III trial protocol and the current clinical commencement and completion of the study.

Further details can be viewed at:

For further details click here

Share this article